Compare GLDD & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLDD | NBTX |
|---|---|---|
| Founded | 1890 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2007 | 2018 |
| Metric | GLDD | NBTX |
|---|---|---|
| Price | $16.94 | $34.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $17.00 | ★ $26.00 |
| AVG Volume (30 Days) | ★ 2.1M | 34.4K |
| Earning Date | 05-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.57 | N/A |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $702,503,000.00 | N/A |
| Revenue This Year | $3.79 | N/A |
| Revenue Next Year | $9.01 | $11.73 |
| P/E Ratio | $15.70 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.51 | $2.95 |
| 52 Week High | $16.99 | $37.11 |
| Indicator | GLDD | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 68.29 | 69.64 |
| Support Level | $14.60 | $20.11 |
| Resistance Level | $16.99 | N/A |
| Average True Range (ATR) | 0.05 | 2.03 |
| MACD | -0.09 | 0.84 |
| Stochastic Oscillator | 65.38 | 80.35 |
Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The Company is also fully engaged in expanding its core business into the offshore energy industry. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Company work generally is to performed in coastal waterways and deep water ports. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.